Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Gliomas are brain tumors characterized by an immunosuppressive microenvironment. Immunostimulatory agonistic CD40 antibodies (αCD40) are in clinical development for solid tumors, but are yet to be evaluated for glioma. Here, we demonstrate that systemic delivery of αCD40 in preclinical glioma models...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hooren, Luuk, Vaccaro, Alessandra, Ramachandran, Mohanraj, Vazaios, Konstantinos, Libard, Sylwia, van de Walle, Tiarne, Georganaki, Maria, Huang, Hua, Pietilä, Ilkka, Lau, Joey, Ulvmar, Maria H., Karlsson, Mikael C. I., Zetterling, Maria, Mangsbo, Sara M., Jakola, Asgeir S., Olsson Bontell, Thomas, Smits, Anja, Essand, Magnus, Dimberg, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257767/
https://www.ncbi.nlm.nih.gov/pubmed/34226552
http://dx.doi.org/10.1038/s41467-021-24347-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257767/
https://www.ncbi.nlm.nih.gov/pubmed/34226552
http://dx.doi.org/10.1038/s41467-021-24347-7

Ejemplares similares